Early lymphocyte recovery as manifested by an absolute lymphocyte count at d+15 (ALC-15) ≥ 0.5 × 109/L after autologous hematopoietic stem cell transplantation (AHCT) has been associated with a better outcome. This prospective multicenter study aimed to clarify factors associated with ALC-15 ≥ 0.5 × 109/L after AHCT among 178 patients with non-Hodgkin lymphoma. The mobilization capacity, as manifested by peak blood CD34+cell numbers > 45 × 106/L correlated with higher ALC-15 levels (p= 0.020). In addition, the amount of CD3+CD4+T cells > 31.8 × 106/kg in the infused graft predicted ALC-15 ≥ 0.5 × 109/L (p< 0.001). Also, the number of infused graft CD3+CD8+T cells > 28.8 × 106/kg (p= 0.017) and NK cells > 4.4 × 106/kg was linked with higher ALC-15 (p< 0.001). The two-year progression-free survival after AHCT was significantly better in patients with ALC-15 ≥ 0.5 × 109/L (74 vs. 57%,p= 0.027). The five-year OS in patients with higher ALC-15 was 78% vs. 60% in those with lower ALC-15 (p= 0.136). To conclude, the mobilization capacity of CD34+cells and detailed measures of graft cellular content mark prognostic tools that predict ALC-15 ≥ 0.5 × 109/L, which is associated with a better outcome in NHL patients after AHCT.
自体造血干细胞移植后第15天绝对淋巴细胞计数≥0.5×10⁹/L所体现的早期淋巴细胞恢复，与良好预后相关。这项前瞻性多中心研究旨在明确178例非霍奇金淋巴瘤患者移植后达到ALC-15≥0.5×10⁹/L的相关因素。研究显示：以外周血CD34⁺细胞峰值>45×10⁶/L为表征的动员能力与较高的ALC-15水平相关（p=0.020）；同时，回输移植物中CD3⁺CD4⁺T细胞含量>31.8×10⁶/kg可预测ALC-15≥0.5×10⁹/L（p<0.001）；此外，移植物中CD3⁺CD8⁺T细胞>28.8×10⁶/kg（p=0.017）与NK细胞>4.4×10⁶/kg（p<0.001）均与较高ALC-15水平相关。ALC-15≥0.5×10⁹/L患者移植后两年无进展生存率显著更优（74%对57%，p=0.027），五年总生存率在ALC-15较高组达78%，较低组为60%（p=0.136）。综上，CD34⁺细胞动员能力及移植物细胞成分的精细检测可作为预测ALC-15≥0.5×10⁹/L的预后指标，该指标与自体移植后非霍奇金淋巴瘤患者的良好临床结局密切相关。
肿瘤(癌症)患者之家